BlueWillow’s intranasal W805EC (NanoVax®) has demonstrated safety in humans in two completed clinical trials with one trial ongoing. This platform technology overcomes the safety hurdle that slowed intranasal vaccine development for many years. The adjuvant has been shown throughout the development process including three toxicity studies and three clinical trials to not cause any CNS or other toxicity.
The emulsion technology is comprised of simple components including water, a natural oil, and a cationic surfactant safely used for decades in products such as mouthwash. The unique formulation approach isolates antigens within the emulsion until they are efficiently delivered to APCs (antigen-presenting-cells) for immune system processing. It’s an elegantly simple approach enabling safe and effective intranasal vaccination.
News
- H5 Influenza (Pandemic Flu) Clinical Trial Successful, Peer-Reivewed and Accepted for Publication
- BlueWillow Biologics to Present Significant Progress on Its Novel Intranasal Vaccine Technology at World Vaccine Congress Europe
- Dr. Shabaana Khader, University of Chicago, highlights promise of intranasal mucosal vaccine strategy for tuberculosis.
Contact
BlueWillow Biologics, Inc.
2311 Green Rd. Suite A
Ann Arbor, MI 48105
734-302-4000
734-302-9150 fax